CA2864797C - Methods of treating amyotrophic lateral sclerosis - Google Patents

Methods of treating amyotrophic lateral sclerosis Download PDF

Info

Publication number
CA2864797C
CA2864797C CA2864797A CA2864797A CA2864797C CA 2864797 C CA2864797 C CA 2864797C CA 2864797 A CA2864797 A CA 2864797A CA 2864797 A CA2864797 A CA 2864797A CA 2864797 C CA2864797 C CA 2864797C
Authority
CA
Canada
Prior art keywords
compound
als
administration
oxidative stress
stress associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2864797A
Other languages
English (en)
French (fr)
Other versions
CA2864797A1 (en
Inventor
Per Gjorstrup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ANIDA PHARMA Inc
Original Assignee
ANIDA PHARMA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ANIDA PHARMA Inc filed Critical ANIDA PHARMA Inc
Publication of CA2864797A1 publication Critical patent/CA2864797A1/en
Application granted granted Critical
Publication of CA2864797C publication Critical patent/CA2864797C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2864797A 2012-02-15 2013-02-15 Methods of treating amyotrophic lateral sclerosis Active CA2864797C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261599096P 2012-02-15 2012-02-15
US61/599,096 2012-02-15
PCT/US2013/026284 WO2013123290A1 (en) 2012-02-15 2013-02-15 Methods of treating amyotrophic lateral sclerosis

Publications (2)

Publication Number Publication Date
CA2864797A1 CA2864797A1 (en) 2013-08-22
CA2864797C true CA2864797C (en) 2022-03-22

Family

ID=48984729

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2864797A Active CA2864797C (en) 2012-02-15 2013-02-15 Methods of treating amyotrophic lateral sclerosis

Country Status (5)

Country Link
US (1) US9340483B2 (cg-RX-API-DMAC7.html)
EP (1) EP2814479B1 (cg-RX-API-DMAC7.html)
JP (1) JP6173352B2 (cg-RX-API-DMAC7.html)
CA (1) CA2864797C (cg-RX-API-DMAC7.html)
WO (1) WO2013123290A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3570827B1 (en) * 2017-01-18 2025-06-25 Universitat Autònoma de Barcelona Maresin for use in treating multiple sclerosis and amyotrophic lateral sclerosis
WO2019016580A1 (en) 2017-07-20 2019-01-24 Universitat Autonoma De Barcelona MARESINS FOR USE IN THE TREATMENT OF CNS INJURIES
US10322114B2 (en) 2017-07-31 2019-06-18 Above And Beyond Nb, Llc Formulation of a riluzole solution with beta-cyclodextrins
WO2023250031A1 (en) * 2022-06-21 2023-12-28 Anida Pharma Inc. Compositions and methods for treating hearing and ocular disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL151299A0 (en) 2000-02-16 2003-04-10 Brigham & Womens Hospital Aspirin-triggered lipid mediators
AU2002343609B2 (en) * 2001-11-16 2008-12-11 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
WO2004093802A2 (en) * 2003-04-17 2004-11-04 The Board Of Trustees Of The Leland Stanford Junior University Prevention of deficits in neurogenesis with anti-inflammatory agents
EP1660069A4 (en) * 2003-08-05 2009-03-18 Univ Louisiana State NEUROPROTECTION AGAINST CELL APOPTOSIS, NEURAL STROKES, ALZHEIMER DISEASE AND RETINAL DEGENERATION
JP5248779B2 (ja) * 2003-12-01 2013-07-31 ケンブリッジ エンタープライズ リミティド 抗炎症剤
WO2007041440A2 (en) 2005-10-03 2007-04-12 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
EP2120920A4 (en) * 2007-02-20 2011-06-15 Martek Biosciences Corp OXYLIPINES OF LONG-CHAIN MULTIPLE-UNSATURATED FATTY ACIDS AND METHOD FOR THEIR PREPARATION AND USE
US20100303887A1 (en) * 2007-07-30 2010-12-02 Bazan Nicolas G DHA and PEDF, a Therapeutic Composition for Nerve and Retinal Pigment Epithelial Cells
GB2452696B (en) * 2007-08-02 2009-09-23 Cambridge Entpr Ltd 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions
EP2207543A2 (en) * 2007-09-14 2010-07-21 Resolvyx Pharmaceuticals, Inc. Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for treating autoimmune diseases or inhibiting immune function
KR20100100818A (ko) 2007-10-31 2010-09-15 프로노바 바이오파마 노르지 에이에스 새로운 dha 유도체 및 약물로서 그들의 사용
US7782152B2 (en) 2008-08-14 2010-08-24 Broadcom Corporation Monotonic frequency tuning technique for DCXO in cellular applications
US20120122816A1 (en) 2009-02-05 2012-05-17 Resolvyx Pharmaceuticals, Inc. Compositions and methods for organ preservation
EP2961401B1 (en) * 2013-02-28 2019-11-13 Anida Pharma Inc. Methods of treating ototoxicity

Also Published As

Publication number Publication date
JP6173352B2 (ja) 2017-08-02
WO2013123290A1 (en) 2013-08-22
US9340483B2 (en) 2016-05-17
JP2015510517A (ja) 2015-04-09
CA2864797A1 (en) 2013-08-22
WO2013123290A9 (en) 2014-09-12
EP2814479B1 (en) 2019-09-04
EP2814479A4 (en) 2015-07-01
US20150010549A1 (en) 2015-01-08
EP2814479A1 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
US20240180919A1 (en) Ezh2 inhibitors for treating cancer
US11591353B2 (en) Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
US11786533B2 (en) Use of EZH2 inhibitors for treating cancer
JP2020189864A (ja) カルビドパおよびl−ドーパプロドラッグならびにそれらの使用方法
AU2020358970B2 (en) Chinone-, hydrochinome- and naphthochinone-analogues of vatiquione for treatment of mitochondrial disorder diseases
WO2019147783A1 (en) Sulfonamide derivatives for protein degradation
WO2018183923A1 (en) Methods of using ehmt2 inhibitors
CA3212170A1 (en) Novel high penetration drugs and their compositions thereof for treatment of parkinson diseases
TWI886093B (zh) D-絲胺酸之氘化類似物及其用途
JP2024515062A (ja) 重水素化dhodh阻害剤
US9340483B2 (en) Methods of treating amyotrophic lateral sclerosis
WO2021027744A1 (zh) 3-羟基-5-孕烷-20-酮衍生物及其用途
JP2024546138A (ja) トリプタミンプロドラッグ
US9987244B2 (en) Methods of treating ototoxicity
US20100273787A1 (en) Kynurenine-aminotransferase inhibitors
CN114728920B (zh) 一种沃替西汀前药及其应用
IL317344A (en) Substances and their use for the treatment of mental or neurological diseases
CN104822647B (zh) 四氢异葎草酮的衍生物,制造和使用方法
WO2022022472A1 (zh) 烟酰胺核苷芳甲酸酯类化合物及其组合物的用途以及化合物晶型
WO2025259966A1 (en) Pharmaceutical formulations comprising a salt of a docosahexaenoic acid (dha) analog

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180215

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260312

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260313

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260330

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260420